Department of Clinical Oncology and Palliative Care, Zealand University Hospital, Roskilde and Naestved, Denmark.
Department of Oncology R, Odense University Hospital, Odense C, Denmark.
Acta Oncol. 2022 Mar;61(3):363-370. doi: 10.1080/0284186X.2021.2007283. Epub 2021 Nov 30.
Prevalence of peripheral neuropathy (PN) has been studied in patients undergoing treatment with taxanes, platinums and vinca alkaloids. The prevalence is unknown in the general oncological cancer population, characterized by advanced age, comorbidities and heterogeneous treatments.
A cross-sectional survey was administered to all adult patients, attending outpatient services at three Danish departments of oncology. The survey contained the EORTC-CIPN20, the EORTC-QLQ-C30, the GAD7 and PHQ9 questionnaires. A high PN symptom score was defined as a summary score ≥30 points on the CIPN20. P-values were adjusted for multiple testing.
With an overall response rate of 83% (2839 patients), prevalence of PN was 17% overall, varying from 6 to 33% between diagnosis groups.A high score was more common among females (19 vs. 14%, = .008), smokers (21 vs. 15%, = .04), patients living alone (21 vs. 15%, = .002) and patients using cannabis (29 vs. 15%, < .001), as well as patients suffering from diabetes (26 vs. 16%, < .001), cardiac heart disease (27 vs. 16%, < .001), arthritis (32 vs. 15%, < .001) or chronic obstructive pulmonary disease (25 vs. 16%, = .01). High score patients were also older (69ys vs 67ys, = .048) and more likely experiencing polypharmacy (OR = 3.38 [95% CI, 2.64;4.35]).Patients with a high CIPN20 symptom score scored worse on all EORTC QLQ-C30 function and symptom scales. The mean adjusted C30 SumScore difference was -18.66 ([95% CI, -20.31; -17.02], < .001).
Symptoms of PN are experienced widely across cancer groups in the oncology setting. PN symptoms were associated with clinically relevant worse health-related quality of life and with patient-related factors as living alone, various comorbidities, polypharmacy, and cannabis use.
周围神经病变（PN）的患病率已在接受紫杉烷、铂类和长春碱类药物治疗的患者中进行了研究。在以高龄、合并症和异质性治疗为特征的一般肿瘤癌症人群中，其患病率尚不清楚。
对丹麦三个肿瘤学系的所有成年门诊患者进行了横断面调查。该调查包括 EORTC-CIPN20、EORTC-QLQ-C30、GAD7 和 PHQ9 问卷。高 PN 症状评分的定义为 CIPN20 的综合评分≥30 分。P 值经过多次测试调整。
总体应答率为 83%（2839 例），PN 的总体患病率为 17%，在不同诊断组之间为 6%至 33%。女性（19%比 14%，=0.008）、吸烟者（21%比 15%，=0.04）、独居者（21%比 15%，=0.002）和使用大麻者（29%比 15%，<0.001）中高分更为常见，以及患有糖尿病（26%比 16%，<0.001）、心脏病（27%比 16%，<0.001）、关节炎（32%比 15%，<0.001）或慢性阻塞性肺疾病（25%比 16%，=0.01）的患者也更为常见。高分患者年龄更大（69 岁比 67 岁，=0.048），更有可能同时使用多种药物（OR=3.38[95%CI，2.64；4.35]）。高 CIPN20 症状评分患者在 EORTC QLQ-C30 的所有功能和症状量表上的评分均较差。调整后的 C30 总评分平均差值为-18.66[95%CI，-20.31；-17.02]，<0.001）。
在肿瘤学环境中，癌症患者普遍存在 PN 症状。PN 症状与临床相关的健康相关生活质量下降以及与患者相关的因素相关，例如独居、各种合并症、多药治疗和大麻使用。
